inPractice® - Sofosbuvir/Velpatasvir

Management of Hepatitis C Infection

Authors: Jordan J. Feld, MD, MPH; Hemant Shah, MD, MScCH HPTE (More Info)
Editor In Chief: Stefan Zeuzem, MD
Last Reviewed: 1/9/21 (What's New)

Summary

Sofosbuvir/velpatasvir for 12 weeks is approved for use in patients with genotype 1-6 HCV infection with compensated cirrhosis^{[FDA Sofosbuvir Velpatasvir]}
Sofosbuvir/velpatasvir plus ribavirin for 12 weeks is approved for use in patients with genotype 1-6 HCV infection with decompensated cirrhosis^{[FDA Sofosbuvir Velpatasvir]}
High SVR12 rates observed in phase III trials in patients with compensated cirrhosis

Action required

Login now to access all of your entitled content
or
View additional options to gain access to this content

Keywords: Hepatitis C-Treatment